-DOCSTART-	O

Title	O
:	O
Heparan	B-I
sulfate	I-I
in	O
the	O
treatment	O
of	O
intermittent	O
claudication	O
:	O
results	O
of	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
doubleblind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
,	O
performed	O
in	O
24	O
Italian	O
centers	O
.	O

Two	B-P
hundred	I-P
seventeen	I-P
patients	I-P
with	I-P
intermittent	I-P
claudication	I-P
(	I-P
stages	I-P
IIa	I-P
and	I-P
IIb	I-P
of	I-P
Fontaine	I-P
'	I-P
s	I-P
PAD	I-P
classification	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
heparan	B-I
sulfate	I-I
(	O
40	O
mg	O
orally	O
twice	O
a	O
day	O
)	O
or	O
placebo	B-C
for	O
6	O
months	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
an	B-O
increase	I-O
in	I-O
pain	I-O
-	I-O
free	I-O
walking	I-O
distance	I-O
[	O
initial	B-O
claudication	I-O
distance	I-O
(	I-O
ICD	I-O
)	I-O
]	O
during	O
the	O
24	O
weeks	O
of	O
treatment	O
.	O

The	B-O
pain	I-O
-	I-O
free	I-O
and	O
the	B-O
absolute	I-O
walking	I-O
distance	I-O
(	I-O
ACD	I-O
)	I-O
were	O
monitored	O
by	O
standardized	B-O
treadmill	I-O
test	I-O
at	O
baseline	O
and	O
at	O
4	O
,	O
12	O
and	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
valociclovir	B-I
hydrochloride	I-I
on	O
patients	B-P
with	I-P
herpes	I-P
zoster	I-P
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Marimastat	B-I
as	O
maintenance	O
therapy	O
for	O
patients	B-P
with	I-P
advanced	I-P
gastric	I-P
cancer	I-P
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
and	I-P
sixty	I-P
-	I-P
nine	I-P
patients	I-P
with	I-P
histological	I-P
proof	I-P
of	I-P
adenocarcinoma	I-P
,	O
who	O
had	O
received	O
no	O
more	O
than	O
a	O
single	O
regimen	O
of	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
,	O
were	O
randomised	O
to	O
receive	O
either	O
marimastat	B-I
(	O
10	O
mg	O
b	O
.	O
d	O
.	O
)	O
or	O
placebo	B-C
.	O

Patients	O
were	O
treated	O
for	O
as	O
long	O
as	O
was	O
tolerable	O
.	O

The	O
primary	O
endpoint	O
was	O
overall	B-O
survival	I-O
with	O
secondary	O
endpoints	O
of	O
time	B-O
to	I-O
disease	I-O
progression	I-O
and	O
quality	B-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Overexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
cellular	O
receptor	O
KDR	O
(	O
VEGFR	O
-	O
2	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	B-P
with	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Pain	B-I
and	I-I
fatigue	I-I
management	I-I
:	O
results	O
of	O
a	O
nursing	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Chemotherapy	O
clinics	O
of	O
two	O
comprehensive	O
and	O
two	O
community	O
cancer	O
centers	O
.	O

Interviews	O
were	O
conducted	O
at	O
baseline	O
and	O
10	O
and	O
20	O
weeks	O
.	O

An	B-I
18	I-I
-	I-I
week	I-I
,	I-I
10	I-I
-	I-I
contact	I-I
nursing	I-I
intervention	I-I
utilizing	O
problem	B-I
-	I-I
solving	I-I
approaches	I-I
to	I-I
symptom	I-I
management	I-I
and	O
improving	B-I
physical	I-I
functioning	I-I
and	O
emotional	B-I
health	I-I
was	O
implemented	O
.	O

The	O
sample	O
consisted	O
of	O
53	O
patients	O
in	O
the	O
experimental	O
arm	O
and	O
60	O
in	O
the	O
control	O
arm	O
who	O
reported	O
pain	B-O
and	O
fatigue	B-O
at	O
baseline	O
.	O

Pain	B-O
and	O
fatigue	B-O
,	O
numbers	B-O
of	I-O
other	I-O
symptoms	I-O
,	O
and	O
physical	B-O
role	I-O
impact	I-O
and	O
social	B-O
-	I-O
functioning	I-O
subscales	I-O
from	O
the	B-O
Medical	I-O
Outcomes	I-O
Study	I-O
36	I-O
Short	I-O
Form	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
secretin	B-I
:	O
effects	O
on	O
aberrant	O
behavior	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
examined	O
the	O
effect	O
of	O
a	B-I
single	I-I
dose	I-I
of	I-I
synthetic	I-I
human	I-I
secretin	I-I
on	O
aberrant	B-O
behavior	I-O
.	O

Parent	O
and	O
teacher	O
data	O
from	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
for	O
eight	B-P
male	I-P
children	I-P
were	O
analyzed	O
for	O
reliable	O
change	O
in	O
a	O
clinical	O
replication	O
series	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	B-P
cell	I-P
lung	I-P
cancer	I-P
patients	I-P
.	O

METHODS	O
:	O
Fresh	B-I
venous	I-I
blood	I-I
was	O
taken	O
throughout	O
treatment	O
and	O
follow	O
-	O
up	O
.	O

Aliquots	O
were	O
stained	O
with	O
a	B-I
"	I-I
tumour	I-I
-	I-I
specific	I-I
"	I-I
antibody	I-I
against	I-I
epithelial	I-I
tissue	I-I
(	I-I
Ber	I-I
EP4	I-I
)	I-I
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O

Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead	O
-	O
antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	B-O
cell	I-O
identity	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Oral	B-I
desensitization	I-I
in	O
papular	O
urticaria	O
in	O
children	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
blind	O
placebo	O
controlled	O
study	O
,	O
an	B-I
oral	I-I
vaccine	I-I
prepared	O
from	O
insect	O
saliva	O
was	O
compared	O
with	O
placebo	B-C
(	I-C
stable	I-C
vaccine	I-C
solvent	I-C
)	I-C
.	O

Vaccine	B-I
and	O
placebo	B-C
effectiveness	B-O
were	O
tested	O
by	O
counting	O
active	B-O
PU	I-O
lesions	I-O
,	O
serum	B-O
eosinophils	I-O
,	O
and	O
IgE	B-O
,	O
before	O
and	O
after	O
4	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Combined	O
therapy	O
in	O
the	O
treatment	O
of	O
primary	O
mediastinal	O
B	O
-	O
cell	O
lymphoma	O
:	O
conventional	B-C
versus	O
escalated	B-I
chemotherapy	I-I
.	O

METHODS	O
:	O
From	O
1989	O
to	O
1997	O
,	O
68	B-P
patients	I-P
diagnosed	I-P
with	I-P
previously	I-P
untreated	I-P
PMBCL	I-P
,	I-P
aged	I-P
18	I-P
-	I-P
65	I-P
years	I-P
and	I-P
negative	I-P
for	I-P
immunodeficiency	I-P
virus	I-P
test	I-P
,	O
were	O
considered	O
candidates	O
to	O
receive	O
either	O
conventional	B-C
chemotherapy	I-C
with	I-C
CEOP	I-C
-	I-C
Bleo	I-C
(	O
cyclophosphamide	B-C
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-C
1	O
.	O
4	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
prednisone	B-C
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-C
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
bleomycin	B-C
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
mega	B-I
CEOP	I-I
-	I-I
Bleo	I-I
(	O
cyclophosphamide	B-I
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-I
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-I
,	O
prednisone	B-I
,	O
and	O
bleomycin	B-I
at	O
the	O
same	O
doses	O
)	O
every	O
21	O
days	O

for	O
six	O
cycles	O
,	O
followed	O
by	O
radiotherapy	B-I
to	I-I
the	I-I
mediastinum	I-I
with	O
the	B-I
mantle	I-I
technique	I-I
(	O
35	O
-	O
45	O
Gy	O
,	O
mean	O
38	O
Gy	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
sleep	I-I
studies	I-I
in	O
the	O
assessment	O
of	O
sleep	O
apnea	O
/	O
hypopnea	O
syndrome	O
.	O

METHODS	O
:	O
Prospective	O
case	O
study	O
.	O

The	O
sleep	O
-	O
disorders	O
unit	O
of	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O

Fifty	B-P
-	I-P
five	I-P
patients	I-P
suspected	I-P
of	I-P
having	I-P
SAHS	I-P
and	I-P
living	I-P
within	I-P
30	I-P
km	I-P
of	I-P
our	I-P
laboratory	I-P
.	O

Patients	O
were	O
studied	O
first	O
in	O
their	O
homes	O
with	O
the	B-I
limited	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
.	O

Polysomnography	B-I
was	O
performed	O
within	O
30	O
days	O
of	O
the	O
first	O
study	O
.	O

Both	O
studies	O
were	O
read	O
by	O
independent	O
investigators	O
blinded	O
to	O
the	O
results	O
of	O
the	O
other	O
study	O
.	O

Diagnoses	B-O
and	O
therapeutic	B-O
decisions	I-O
regarding	O
the	B-O
use	I-O
of	I-O
continuous	I-O
positive	I-O
airway	I-O
pressure	I-O
obtained	O
from	O
the	O
home	O
and	O
laboratory	O
studies	O
were	O
compared	O
.	O

Agreement	O
between	O
the	O
home	O
and	O
laboratory	O
study	O
recordings	O
was	O
also	O
assessed	O
using	O
receiver	B-O
operating	I-O
characteristic	I-O
(	I-O
ROC	I-O
)	I-O
curves	I-O
and	O
Bland	B-O
-	I-O
Altman	I-O
analysis	I-O
.	O

One	O
half	O
of	O
the	O
home	O
studies	O
were	O
randomly	O
assigned	O
to	O
be	O
performed	O
with	O
a	B-I
sleep	I-I
technician	I-I
'	I-I
s	I-I
set	I-I
up	I-I
of	I-I
the	I-I
equipment	I-I
in	I-I
the	I-I
patient	I-I
'	I-I
s	I-I
home	I-I
(	O
group	O
1	O
)	O
,	O
and	O
the	O
other	O
half	O
with	O
the	B-I
patient	I-I
'	I-I
s	I-I
own	I-I
setup	I-I
of	I-I
the	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
(	O
group	O
2	O
)	O
,	O
after	O
an	O
instruction	O
period	O
in	O
the	O
hospital	O
.	O

An	O
economic	O
analysis	O
was	O
performed	O
,	O
considering	O
the	O
cost	O
of	O
repeating	O
studies	O
in	O
cases	O
with	O
faulty	O
or	O
inconclusive	O
home	O
studies	O
(	O
these	O
patients	O
should	O
undergo	O
polysomnography	O
as	O
a	O
second	O
step	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Transurethral	O
prostate	O
resection	O
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
of	O
role	O
of	O
finasteride	B-I
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
70	I-P
patients	I-P
scheduled	I-P
to	I-P
undergo	I-P
elective	I-P
transurethral	I-P
prostate	I-P
resection	I-P
were	O
randomized	O
to	O
receive	O
5	B-I
mg	I-I
.	I-I

finasteride	I-I
daily	O
or	O
placebo	B-C
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	B-O
hemoglobin	I-O
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	B-O
volume	I-O
of	I-O
irrigation	I-O
fluid	I-O
used	O
and	O
its	B-O
hemoglobin	I-O
concentration	I-O
as	O
well	O
as	B-O
resected	I-O
prostate	I-O
weight	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
to	O
assess	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
for	O
the	O
treatment	O
of	O
multiple	O
actinic	O
keratoses	O
.	O

METHODS	O
:	O
Patients	O
in	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
applied	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
or	O
vehicle	B-C
to	O
AK	O
lesions	O
3	O
times	O
per	O
week	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
or	O
until	O
lesions	O
had	O
resolved	O
.	O

In	O
the	O
event	O
of	O
an	O
adverse	O
reaction	O
,	O
application	O
of	O
imiquimod	B-I
was	O
reduced	O
to	O
1	O
or	O
2	O
times	O
per	O
week	O
.	O

Rest	O
periods	O
were	O
also	O
allowed	O
if	O
necessary	O
.	O

A	O
specialized	O
outpatient	O
dermatology	O
clinic	O
within	O
a	O
state	O
-	O
funded	O
hospital	O
in	O
Germany	O
.	O

The	O
study	O
population	O
was	O
aged	O
45	O
to	O
85	O
years	O
.	O

Of	O
52	O
patients	O
screened	O
,	O
36	B-P
men	I-P
and	I-P
women	I-P
with	I-P
AK	I-P
confirmed	I-P
by	I-P
histological	I-P
diagnosis	I-P
were	I-P
enrolled	I-P
.	O

Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
did	O
not	O
have	O
a	O
histological	O
diagnosis	O
for	O
AK	O
,	O
if	O
they	O
were	O
older	O
than	O
85	O
years	O
,	O
or	O
if	O
they	O
did	O
not	O
comply	O
with	O
the	O
protocol	O
.	O

All	O
patients	O
had	O
responded	O
to	O
a	O
notice	O
asking	O
for	O
volunteers	O
.	O

The	B-O
number	I-O
and	O
appearance	B-O
of	I-O
lesions	I-O
were	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
treatment	O
.	O

All	O
adverse	O
effects	O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetics	O
of	O
azithromycin	B-I
in	O
lung	O
tissue	O
,	O
bronchial	O
washing	O
,	O
and	O
plasma	O
in	O
patients	B-P
given	I-P
multiple	I-P
oral	I-P
doses	I-P
of	I-P
500	I-P
and	I-P
1000	I-P
mg	I-P
daily	I-P
.	O

METHODS	O
:	O
Samples	O
were	O
taken	O
during	O
surgery	O
for	O
lung	O
resection	O
at	O
various	O
time	O
points	O
up	O
to	O
204	O
h	O
after	O
the	O
last	O
drug	O
dose	O
,	O
and	O
azithromycin	B-O
levels	I-O
were	O
analyzed	O
by	O
HPLC	B-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
effects	O
of	O
eptifibatide	B-I
in	O
planned	O
coronary	O
stent	O
implantation	O
in	O
patients	B-P
with	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	O
ESPRIT	O
Trial	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
S	B-I
-	I-I
phase	I-I
kinase	I-I
-	I-I
associated	I-I
protein	I-I
2	I-I
expression	I-I
in	O
laryngeal	O
squamous	O
cell	O
carcinomas	O
and	O
its	O
prognostic	O
implications	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
a	B-O
potential	I-O
distribution	I-O
of	I-O
Skp2	I-O
in	I-O
LSCC	I-O
and	O
its	O
clinical	B-O
implications	I-O
was	O
investigated	O
by	O
an	O
immunohistochemical	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Sustained	O
ventricular	O
arrhythmias	O
and	O
mortality	O
among	O
patients	B-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
:	O
results	O
from	O
the	O
GUSTO	O
-	O
III	O
trial	O
.	O

METHODS	O
:	O
We	O
identified	O
independent	B-O
predictors	I-O
of	I-O
inhospital	I-O
ventricular	I-O
fibrillation	I-O
(	I-O
VF	I-O
)	I-O
and	O
ventricular	B-O
tachycardia	I-O
(	I-O
VT	I-O
)	I-O
and	O
compared	O
30	O
-	O
day	O
and	O
1	O
-	O
year	O
mortality	B-O
rates	I-O
of	O
patients	O
who	O
did	O
(	O
n	O
=	O
1121	O
)	O
and	O
did	O
not	O
(	O
n	O
=	O
13	O
,	O
921	O
)	O
have	O
these	O
arrhythmias	O
during	O
the	O
index	O
hospitalization	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
-	O
response	O
characteristics	O
during	O
long	B-I
-	I-I
term	I-I
inhalation	I-I
of	I-I
nitric	I-I
oxide	I-I
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
for	O
conventional	B-C
therapy	I-C
(	O
control	O
)	O
or	O
continuous	B-I
treatment	I-I
with	I-I
10	I-I
parts	I-I
per	I-I
million	I-I
(	I-I
ppm	I-I
)	I-I
inhaled	I-I
NO	I-I
until	O
weaning	O
was	O
initiated	O
.	O

We	O
measured	O
DR	B-O
curves	I-O
of	I-O
PaO2	I-O
/	O
FIO2	B-O
versus	O
the	B-O
inhaled	I-O
NO	I-O
dose	I-O
at	O
regular	O
intervals	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exposure	O
prevention	O
rating	O
method	O
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O

METHODS	O
:	O
We	O
developed	O
a	B-I
checklist	I-I
containing	O
six	O
unique	O
sets	O
of	O
yes	O
/	O
no	O
variables	O
organized	O
in	O
a	O
2	O
x	O
3	O
matrix	O
of	O
exposure	O
potential	O
versus	O
protection	O
(	O
two	O
columns	O
)	O
at	O
the	O
levels	O
of	O
materials	O
,	O
processes	O
,	O
and	O
human	O
interface	O
(	O
three	O
rows	O
)	O
.	O

The	O
three	O
levels	O
correspond	O
to	O
a	O
simplified	O
hierarchy	O
of	O
controls	O
.	O

Each	O
of	O
the	O
six	O
sets	O
of	O
indicator	O
variables	O
was	O
reduced	O
to	O
a	O
high	O
/	O
moderate	O
/	O
low	O
rating	O
.	O

Ratings	O
from	O
the	O
matrix	O
were	O
then	O
combined	O
to	O
generate	O
a	O
single	O
overall	O
exposure	O
prevention	O
rating	O
for	O
each	O
area	O
.	O

Reflecting	O
the	O
hierarchy	O
of	O
controls	O
,	O
material	O
factors	O
were	O
weighted	O
highest	O
,	O
followed	O
by	O
process	O
,	O
and	O
then	O
human	O
interface	O
.	O

The	B-I
checklist	I-I
was	O
filled	O
out	O
by	O
an	O
industrial	O
hygienist	O
while	O
conducting	O
a	O
walk	O
-	O
through	O
inspection	O
(	O
N	O
=	O
131	O
manufacturing	O
processes	O
/	O
areas	O
in	O
17	O
large	O
work	O
sites	O
)	O
.	O

One	B-O
area	I-O
or	O
process	B-O
per	I-O
manufacturing	I-O
department	I-O
was	O
assessed	O
and	O
rated	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
trial	O
of	O
the	O
canalith	B-I
repositioning	I-I
procedure	I-I
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
trial	O
in	O
the	O
setting	O
of	O
a	O
neurotological	O
clinic	O
in	O
Thailand	O
.	O

Fifty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
posterior	I-P
benign	I-P
paroxysmal	I-P
positional	I-P
vertigo	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
and	O
control	O
groups	O
using	O
a	O
block	O
of	O
four	O
.	O

The	O
treatment	O
group	O
was	O
treated	O
with	O
the	B-I
modified	I-I
CRP	I-I
technique	I-I
until	O
the	O
nystagmus	O
disappeared	O
.	O

A	O
mastoid	O
oscillator	O
was	O
not	O
used	O
,	O
nor	O
were	O
any	O
instructions	O
given	O
for	O
patients	O
after	O
the	O
maneuver	O
.	O

Both	O
groups	O
recorded	O
the	B-O
daily	I-O
grading	I-O
of	I-O
symptoms	I-O
and	O
the	B-O
amount	I-O
of	I-O
anti	I-O
-	I-O
vertiginous	I-O
drugs	I-O
(	I-O
cinnarizine	I-O
)	I-O
taken	O
.	O

Objective	O
and	O
subjective	O
assessments	O
were	O
made	O
weekly	O
until	O
the	O
nystagmus	O
disappeared	O
or	O
until	O
4	O
weeks	O
had	O
passed	O
since	O
treatment	O
began	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
trial	O
of	O
two	B-I
different	I-I
endoscopic	I-I
resection	I-I
techniques	I-I
for	O
early	O
stage	O
cancer	O
of	O
the	O
esophagus	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
randomized	O
study	O
,	O
100	O
consecutive	O
endoscopic	O
resections	O
were	O
performed	O
in	O
72	B-P
patients	I-P
with	I-P
early	I-P
stage	I-P
esophageal	I-P
cancer	I-P
.	O

Fifty	O
endoscopic	O
resections	O
were	O
performed	O
with	O
a	B-I
"	I-I
suck	I-I
-	I-I
and	I-I
-	I-I
ligate	I-I
"	I-I
device	I-I
without	I-I
prior	I-I
submucosa	I-I
injection	I-I
and	O
50	O
with	O
the	B-I
cap	I-I
technique	I-I
with	I-I
prior	I-I
submucosa	I-I
injection	I-I
of	I-I
a	I-I
dilute	I-I
saline	I-I
solution	I-I
of	I-I
epinephrine	I-I
.	O

The	O
main	O
assessment	O
criteria	O
were	O
maximum	B-O
diameter	I-O
of	I-O
the	I-O
resection	I-O
specimen	I-O
and	O
of	O
the	B-O
resection	I-O
area	I-O
,	O
and	O
the	B-O
complication	I-O
rate	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	O

I	O
:	O
comparison	O
of	O
placebo	B-C
and	O
single	B-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
crossover	O
,	O
double	O
blind	O
,	O
and	O
placebo	O
controlled	O
trial	O
of	O
a	B-I
single	I-I
intravenous	I-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
(	I-I
HSS	I-I
)	I-I
2	O
CU	O
/	O
kg	O
.	O

The	B-P
62	I-P
subjects	I-P
(	I-P
3	I-P
-	I-P
8	I-P
years	I-P
)	I-P
were	O
assigned	O
to	O
group	O
1	O
(	O
saline	B-C
placebo	I-C
/	O
HSS	B-I
)	O
or	O
group	O
2	O
(	O
HSS	B-I
/	O
saline	B-C
placebo	I-C
)	O
.	O

Diagnosis	O
was	O
confirmed	O
by	O
ADI	B-O
-	I-O
R	I-O
(	I-O
Autism	I-O
Diagnostic	I-O
Interview	I-O
-	I-O
Revised	I-O
)	I-O
algorithm	I-O
.	O

Severity	B-O
of	I-O
symptoms	I-O
was	O
rated	O
using	O
the	B-O
CARS	I-O
(	I-O
Childhood	I-O
Autism	I-O
Rating	I-O
Scale	I-O
)	I-O
.	O

Outcome	O
measures	O
included	O
Communication	B-O
and	I-O
Symbolic	I-O
Behavior	I-O
Scale	I-O
(	I-O
CSBS	I-O
)	I-O
,	O
Ritvo	B-O
Real	I-O
-	I-O
life	I-O
Rating	I-O
Scale	I-O
,	O
weekly	B-O
Global	I-O
Rating	I-O
Scale	I-O
(	I-O
GBRS	I-O
)	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
daily	B-O
log	I-O
of	I-O
gastrointestinal	I-O
symptoms	I-O
.	O

The	B-O
communication	I-O
subscale	I-O
of	I-O
the	I-O
CSBS	I-O
,	O
specifying	O
communication	B-O
function	I-O
,	O
reciprocity	B-O
,	O
and	O
social	B-O
-	I-O
affective	I-O
signalling	O
was	O
videotaped	O
and	O
scored	O
by	O
a	O
blinded	O
,	O
trained	O
observer	O
.	O

-DOCSTART-	O

Title	O
:	O
Cone	O
biopsy	O
:	O
has	O
endocervical	B-I
sampling	I-I
a	O
role	O
?	O
.	O

METHODS	O
:	O
A	O
randomized	O
study	O
of	O
two	O
methods	O
of	O
endocervical	O
sampling	O
.	O

Colposcopy	O
clinic	O
at	O
Aberdeen	O
Royal	O
Infirmary	O
.	O

100	B-P
women	I-P
with	I-P
abnormal	I-P
cervical	I-P
smears	I-P
selected	I-P
for	I-P
cone	I-P
biopsy	I-P
according	I-P
to	I-P
current	I-P
colposcopy	I-P
criteria	I-P
.	O

53	O
women	O
were	O
randomized	O
to	O
have	O
endocervical	B-I
sampling	I-I
with	I-I
the	I-I
Kevorkian	I-I
curette	I-I
and	O
47	O
to	O
have	O
sampling	O
with	O
the	B-I
Medscand	I-I
endocervical	I-I
brush	I-I
.	O

Cytology	B-O
and	O
histology	B-O
results	I-O
from	O
endocervical	O
sampling	O
compared	O
with	O
cone	B-O
biopsy	I-O
histology	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Perioperative	B-I
immunotherapy	I-I
with	O
recombinant	B-I
interleukin	I-I
2	I-I
in	O
patients	B-P
undergoing	I-P
surgery	I-P
for	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	O
were	O
randomly	O
allocated	O
to	O
control	O
(	O
n	O
=	O
13	O
)	O
or	O
treatment	O
groups	O
(	O
n	O
=	O
12	O
)	O
.	O

Immunological	B-O
studies	I-O
of	O
both	O
lymphocyte	B-O
function	I-O
and	O
subset	B-O
number	I-O
were	O
performed	O
preoperatively	O
and	O
on	O
Days	O
1	O
,	O
4	O
,	O
7	O
,	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Micronized	B-I
flavonoids	I-I
in	O
pain	O
control	O
after	O
hemorrhoidectomy	O
:	O
a	O
prospective	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
The	B-P
subjects	I-P
were	I-P
112	I-P
consecutive	I-P
patients	I-P
randomly	O
assigned	O
either	O
to	O
receive	O
MFF	B-I
(	O
group	O
1	O
)	O
for	O
1	O
week	O
or	O
not	B-C
to	I-C
receive	I-C
MFF	I-C
,	O
as	O
a	O
control	O
(	O
group	O
2	O
)	O
,	O
after	O
hemorrhoidectomy	O
,	O
The	B-O
severity	I-O
of	I-O
pain	I-O
and	O
the	B-O
number	I-O
of	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
required	O
were	O
recorded	O
for	O
the	O
first	O
3	O
days	O
,	O
then	O
1	O
week	O
after	O
hemorrhoidectomy	O
.	O

The	B-O
number	I-O
of	I-O
days	I-O
that	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
were	O
required	O
,	O
hospital	B-O
stay	I-O
,	O
and	O
patient	B-O
satisfaction	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Parent	O
-	O
defined	O
target	O
symptoms	O
respond	O
to	O
risperidone	B-I
in	O
RUPP	O
autism	O
study	O
:	O
customer	O
approach	O
to	O
clinical	O
trials	O
.	O

METHODS	O
:	O
In	O
the	O
Research	O
Units	O
on	O
Pediatric	O
Psychopharmacology	O
(	O
RUPP	O
)	O
Autism	O
Network	O
8	O
-	O
week	O
double	O
-	O
blind	O
trial	O
of	O
risperidone	B-I
versus	O
placebo	B-C
,	O
the	B-O
chief	I-O
concerns	I-O
of	I-O
parents	I-O
were	O
collected	O
at	O
0	O
,	O
4	O
,	O
and	O
8	O
weeks	O
(	O
endpoint	O
)	O
,	O
in	O
addition	O
to	O
standardized	O
primary	O
measures	O
.	O

Blinded	B-O
clinical	I-O
judges	I-O
rated	O
change	O
from	O
baseline	O
to	O
4	O
and	O
8	O
weeks	O
on	O
a	O
9	O
-	O
point	O
scale	O
(	O
1	O
=	O
normalized	O
,	O
5	O
=	O
unchanged	O
,	O
9	O
=	O
disastrous	O
)	O
;	O
94	O
participants	O
had	O
usable	O
data	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
carbohydrate	I-I
-	I-I
protein	I-I
supplement	I-I
on	O
endurance	O
performance	O
during	O
exercise	O
of	O
varying	O
intensity	O
.	O

METHODS	O
:	O
Nine	B-P
trained	I-P
cyclists	I-P
exercised	I-P
on	I-P
3	I-P
separate	I-P
occasions	I-P
at	I-P
intensities	I-P
that	I-P
varied	I-P
between	I-P
45	I-P
%	I-P
and	I-P
75	I-P
%	I-P
VO2max	I-P
for	I-P
3	I-P
h	I-P
and	I-P
then	I-P
at	I-P
85	I-P
%	I-P
VO2max	I-P
until	I-P
fatigued	I-P
.	O

Supplements	B-I
(	O
200	O
ml	O
)	O
were	O
provided	O
every	O
20	O
min	O
and	O
consisted	O
of	O
placebo	B-C
,	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
solution	I-I
,	O
and	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
/	O
1	B-I
.	I-I
94	I-I
%	I-I
protein	I-I
solution	I-I
.	O

Treatments	O
were	O
administered	O
using	O
a	O
double	O
-	O
blind	O
randomized	O
design	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
sublingual	O
immunotherapy	O
for	O
respiratory	O
allergy	O
is	O
not	O
affected	O
by	O
different	B-I
dosage	I-I
regimens	I-I
in	O
the	O
induction	O
phase	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Combined	B-I
preoperative	I-I
xeloda	I-I
and	O
radiotherapy	B-I
for	O
lower	O
rectal	O
cancer	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
lower	I-P
rectal	I-P
cancer	I-P
patients	I-P
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

30	O
patients	O
(	O
Group	O
A	O
)	O
were	O
treated	O
with	O
operation	B-C
alone	I-C
and	O
30	O
patients	O
(	O
Group	O
B	O
)	O
were	O
treated	O
with	O
xeloda	B-I
and	O
radiotherapy	B-I
before	O
operation	O
.	O

-DOCSTART-	O

Title	O
:	O
Outcomes	O
in	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
in	O
the	O
current	O
era	O
:	O
a	O
report	O
from	O
the	O
Prevention	O
of	O
REStenosis	O
with	O
Tranilast	B-I
and	O
its	O
Outcomes	O
(	O
PRESTO	O
)	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
long	O
-	O
term	O
effect	O
of	O
oxandrolone	B-I
on	O
hepatic	O
acute	O
phase	O
proteins	O
in	O
severely	B-P
burned	I-P
children	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
children	I-P
with	I-P
>	I-P
or	I-P
=40	I-P
%	I-P
total	I-P
body	I-P
surface	I-P
area	I-P
burns	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
oxandrolone	B-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
by	O
mouth	O
twice	O
daily	O
)	O
from	O
postoperative	O
day	O
5	O
to	O
1	O
year	O
postburn	O
.	O

Levels	B-O
of	I-O
constitutive	I-O
proteins	I-O
and	O
acute	B-O
phase	I-O
proteins	I-O
were	O
measured	O
at	O
admission	O
;	O
at	O
discharge	O
;	O
and	O
at	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
burn	O
.	O

Total	B-O
albumin	I-O
supplementation	I-O
and	O
hepatic	B-O
transaminases	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Clonidine	B-I
treatment	I-I
of	O
hyperactive	B-P
and	I-P
impulsive	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	O

METHODS	O
:	O
Eight	B-P
male	I-P
children	I-P
(	I-P
8	I-P
.	I-P
1	I-P
+	I-P
/	I-P
-	I-P
2	I-P
.	I-P
8	I-P
years	I-P
)	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
diagnosed	I-P
by	I-P
DSM	I-P
-	I-P
III	I-P
-	I-P
R	I-P
criteria	I-P
,	O
completed	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
trial	O
of	O
clonidine	B-I
.	O

Subjects	O
were	O
included	O
in	O
the	O
study	O
if	O
they	O
had	O
inattention	O
,	O
impulsivity	O
,	O
and	O
hyperactivity	O
that	O
was	O
excessive	O
for	O
their	O
developmental	O
level	O
.	O

Subjects	O
had	O
not	O
tolerated	O
or	O
responded	O
to	O
other	O
psychopharmacologic	O
treatments	O
(	O
neuroleptics	O
,	O
methylphenidate	O
,	O
or	O
desipramine	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Oscillatory	B-I
potentials	I-I
,	O
retinopathy	B-I
,	O
and	O
long	B-I
-	I-I
term	I-I
glucose	I-I
control	I-I
in	O
insulin	O
-	O
dependent	O
diabetes	O
.	O

METHODS	O
:	O
Individual	B-O
(	O
OP	B-O
-	I-O
1	I-O
,	O
OP	B-O
-	I-O
2	I-O
,	O
OP	B-O
-	I-O
3	I-O
)	O
and	O
summed	B-O
(	I-O
OP	I-O
-	I-O
sum	I-O
)	I-O
amplitudes	I-O
of	I-O
oscillatory	I-O
potentials	I-O
(	I-O
OPs	I-O
)	I-O
of	I-O
electroretinography	I-O
were	O
recorded	O
at	O
study	O
start	O
and	O
7	O
-	O
years	O
later	O
in	O
45	B-P
patients	I-P
(	O
the	O
Oslo	O
study	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	O
combination	O
of	O
evening	B-I
primrose	I-I
oil	I-I
(	I-I
gamma	I-I
linolenic	I-I
acid	I-I
)	I-I
and	O
fish	B-I
oil	I-I
(	O
eicosapentaenoic	B-I
+	O
docahexaenoic	B-I
acid	I-I
)	O
versus	O
magnesium	B-I
,	O
and	O
versus	O
placebo	B-C
in	O
preventing	O
pre	O
-	O
eclampsia	O
.	O

METHODS	O
:	O
All	O
were	O
given	O
as	O
nutritional	B-I
supplements	I-I
for	O
six	O
months	O
to	O
a	B-P
group	I-P
of	I-P
primiparous	I-P
and	I-P
multiparous	I-P
pregnant	I-P
women	I-P
.	O

Some	O
of	O
these	O
women	O
had	O
personal	O
or	O
family	O
histories	O
of	O
hypertension	O
(	O
21	O
%	O
)	O
.	O

Only	O
those	O
patients	O
who	O
received	O
prenatal	O
care	O
at	O
the	O
Central	O
Maternity	O
Hospital	O
for	O
Luanda	O
were	O
included	O
in	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Injection	O
pain	O
and	O
postinjection	O
pain	O
of	O
the	B-I
palatal	I-I
-	I-I
anterior	I-I
superior	I-I
alveolar	I-I
injection	I-I
,	O
administered	O
with	O
the	O
Wand	O
Plus	O
system	O
,	O
comparing	O
2	B-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
to	O
3	B-I
%	I-I
mepivacaine	I-I
.	O

METHODS	O
:	O
Using	O
a	O
crossover	O
design	O
,	O
40	B-P
subjects	I-P
randomly	O
received	O
,	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
P	B-I
-	I-I
ASA	I-I
injections	I-I
of	I-I
1	I-I
.	I-I
4	I-I
mL	I-I
of	I-I
2	I-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
and	O
1	B-I
.	I-I
4	I-I
mL	I-I
of	I-I
3	I-I
%	I-I
mepivacaine	I-I
,	O
at	O
2	O
separate	O
appointments	O
.	O

The	B-I
P	I-I
-	I-I
ASA	I-I
injection	I-I
was	O
administered	O
,	O
utilizing	O
the	O
Wand	O
Plus	O
system	O
,	O
6	O
to	O
10	O
mm	O
into	O
the	O
incisive	O
canal	O
located	O
lingual	O
to	O
the	O
central	O
incisors	O
.	O

The	B-O
pain	I-O
of	I-O
needle	I-O
insertion	I-O
,	O
needle	B-O
placement	I-O
,	O
solution	B-O
deposition	I-O
and	O
postinjection	B-O
pain	I-O
were	O
recorded	O
on	O
a	B-O
Heft	I-O
-	I-O
Parker	I-O
visual	I-O
analog	I-O
scale	I-O
for	O
the	B-I
2	I-I
P	I-I
-	I-I
ASA	I-I
injections	I-I
.	O

Eighty	O
injections	O
were	O
randomly	O
administered	O
in	O
the	O
study	O
,	O
40	O
using	O
topical	B-C
anesthetic	I-C
gel	I-C
and	O
40	O
using	O
a	B-C
placebo	I-C
gel	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Rapid	O
-	O
sequence	O
intubation	O
of	O
head	B-P
trauma	I-P
patients	I-P
:	O
prevention	O
of	O
fasciculations	O
with	O
pancuronium	B-I
versus	O
minidose	B-I
succinylcholine	I-I
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

An	O
inner	O
-	O
city	O
county	O
trauma	O
center	O
with	O
70	O
,	O
000	O
patient	O
visits	O
per	O
year	O
.	O

Sequential	B-P
adult	I-P
head	I-P
trauma	I-P
patients	I-P
requiring	I-P
rapid	I-P
-	I-P
sequence	I-P
intubation	I-P
who	I-P
had	I-P
no	I-P
contraindications	I-P
to	I-P
succinylcholine	I-P
or	I-P
pancuronium	I-P
.	O

Each	O
head	O
trauma	O
patient	O
requiring	O
rapid	O
-	O
sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid	O
-	O
sequence	O
intubation	O
maneuvers	O
and	O
lidocaine	O
(	O
1	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	B-I
succinylcholine	I-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
or	O
pancuronium	B-I
(	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	O
paralytic	O
dose	O
of	O
succinylcholine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Fasciculations	B-O
were	O
recorded	O
using	O
a	B-O
graded	I-O
visual	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metoprolol	B-I
CR	I-I
/	O
XL	B-I
improves	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
In	O
an	O
echocardiographic	O
substudy	O
to	O
the	B-I
Metoprolol	I-I
CR	I-I
/	O
XL	B-I
Randomized	O
Intervention	O
Trial	O
in	O
Heart	O
Failure	O
(	O
MERIT	O
-	O
HF	O
)	O
,	O
66	B-P
patients	I-P
were	O
examined	O
three	O
times	O
during	O
a	O
12	O
-	O
month	O
period	O
blinded	O
to	O
treatment	O
group	O
,	O
assessing	O
left	B-O
ventricular	I-O
dimensions	I-O
and	O
ejection	B-O
fraction	I-O
,	O
and	O
Doppler	B-O
mitral	I-O
inflow	I-O
parameters	I-O
,	O
all	O
measured	O
in	O
a	O
core	O
laboratory	O
.	O

-DOCSTART-	O

Title	O
:	O
Bitewing	O
film	O
quality	O
:	O
a	O
clinical	O
comparison	O
of	O
the	B-I
loop	I-I
vs	O
.	O
holder	B-I
techniques	I-I
.	O

METHODS	O
:	O
Four	O
bitewing	O
films	O
were	O
taken	O
from	O
the	B-P
right	I-P
and	I-P
left	I-P
premolar	I-P
and	I-P
molar	I-P
regions	I-P
of	I-P
45	I-P
dental	I-P
students	I-P
using	O
both	O
the	B-I
bitewing	I-I
holder	I-I
and	O
paper	B-I
loop	I-I
techniques	I-I
.	O

A	B-P
total	I-P
of	I-P
360	I-P
films	I-P
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	B-I
bitewing	I-I
technique	I-I
used	O
.	O

Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	B-O
number	I-O
of	I-O
overlaps	I-O
and	O
the	B-O
percentage	I-O
of	I-O
teeth	I-O
showing	I-O
the	I-O
alveolar	I-O
crest	I-O
;	O
(	O
2	O
)	O
proper	B-O
film	I-O
positioning	I-O
;	O
and	O
(	O
3	O
)	O
the	B-O
percentage	I-O
of	I-O
cone	I-O
cutting	I-O
.	O

A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O

For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O

-DOCSTART-	O

Title	O
:	O
Mouth	B-I
closing	I-I
device	I-I
(	I-I
chinstrap	I-I
)	I-I
reduces	O
mouth	O
leak	O
during	O
nasal	O
CPAP	O
.	O

METHODS	O
:	O
Fifteen	B-P
patients	I-P
with	I-P
mouth	I-P
leak	I-P
complaining	I-P
of	I-P
mouth	I-P
dryness	I-P
and	I-P
nasal	I-P
obstruction	I-P
underwent	O
two	O
consecutive	O
overnight	O
polysomnographies	O
,	O
one	O
with	O
a	B-I
chinstrap	I-I
,	O
in	O
random	O
order	O
.	O

Cephalometry	B-O
with	B-I
and	O
without	B-C
a	I-C
chinstrap	I-C
was	O
randomly	O
performed	O
on	O
six	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Clarithromycin	B-I
reduces	O
the	O
severity	O
of	O
bronchial	O
hyperresponsiveness	O
in	O
patients	B-P
with	I-P
asthma	I-P
.	O

METHODS	O
:	O
Adult	B-P
asthma	I-P
patients	I-P
undergoing	I-P
treatment	I-P
with	I-P
budesonide	I-P
400	I-P
microg	I-P
b	I-P
.	I-P
i	I-P
.	I-P
d	I-P
.	I-P
and	I-P
salbutamol	I-P
200	I-P
microg	I-P
p	I-P
.	I-P
r	I-P
.	I-P
n	I-P
.	I-P
less	I-P
than	I-P
twice	I-P
weekly	I-P
were	O
studied	O
.	O

Arm	O
A	O
(	O
16	O
males	O
/	O
six	O
females	O
,	O
aged	O
48	O
+	O
/	O
-	O
16	O
yrs	O
)	O
received	O
clarithromycin	B-I
250	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
8	O
weeks	O
,	O
arm	O
B	O
(	O
eight	O
males	O
/	O
12	O
females	O
,	O
aged	O
42	O
+	O
/	O
-	O
12	O
yrs	O
)	O
clarithromycin	B-I
250	O
mg	O
t	O
.	O
id	O
.	O
and	O
arm	O
C	O
(	O
six	O
males	O
/	O
15	O
females	O
,	O
aged	O
41	O
+	O
/	O
-	O
16	O
yrs	O
)	O
placebo	B-C
dextrose	I-C
tablets	O
.	O

Bronchial	B-O
hyperresponsiveness	I-O
was	O
quantified	O
by	O
measurement	O
of	O
the	O
provocative	O
dose	O
of	O
methacholine	O
causing	O
a	O
20	O
%	O
fall	O
in	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
PD20	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Chronic	B-I
fatigue	I-I
syndrome	I-I
versus	O
neuroendocrineimmune	B-I
dysfunction	I-I
syndrome	I-I
:	O
differential	O
attributions	O
.	O

METHODS	O
:	O
Nurses	O
and	O
physician	O
assistants	O
(	O
PAs	O
)	O
were	O
presented	O
a	O
case	O
study	O
of	O
a	O
patient	O
with	O
symptoms	O
of	O
CFS	B-I
.	O

They	O
were	O
told	O
that	O
the	O
patient	O
had	O
either	O
"	O
chronic	B-I
fatigue	I-I
syndrome	I-I
,	O
"	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
"	O
or	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
which	O
had	O
formerly	O
been	O
called	O
chronic	O
fatigue	O
syndrome	O
.	O

-DOCSTART-	O

Title	O
:	O
Needle	B-I
versus	O
loop	B-I
diathermy	I-I
excision	I-I
of	I-I
the	I-I
transformation	I-I
zone	I-I
for	O
the	O
treatment	O
of	O
cervical	O
intraepithelial	O
neoplasia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomised	O
controlled	O
trial	O
.	O

A	O
gynaecological	O
oncology	O
centre	O
and	O
a	O
teaching	O
hospital	O
in	O
West	O
London	O
.	O

Four	B-P
hundred	I-P
and	I-P
four	I-P
women	I-P
due	I-P
to	I-P
receive	I-P
treatment	I-P
for	I-P
suspected	I-P
CIN	I-P
.	O

Women	O
were	O
randomised	O
to	O
receive	O
either	O
LLETZ	B-I
or	O
NETZ	B-I
.	O

The	O
study	O
was	O
designed	O
to	O
demostrate	O
a	O
difference	O
in	O
the	B-O
proportion	I-O
of	I-O
women	I-O
with	I-O
clear	I-O
histological	I-O
margins	I-O
of	O
82	O
%	O
for	O
LLETZ	B-I
compared	O
to	O
94	O
%	O
for	O
NETZ	B-I
with	O
90	O
%	O
power	O
at	O
a	O
5	O
%	O
significance	O
level	O
,	O
allowing	O
for	O
absence	O
of	O
CIN	O
in	O
the	O
treatment	O
specimen	O
in	O
15	O
%	O
.	O

-DOCSTART-	O

Title	O
:	O
Public	O
and	O
private	O
heart	O
rate	O
feedback	O
in	O
social	O
phobia	O
:	O
a	O
manipulation	O
of	O
anxiety	O
visibility	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
32	I-P
social	I-P
phobics	I-P
and	I-P
32	I-P
controls	I-P
were	O
asked	O
twice	O
to	O
sit	B-I
in	I-I
a	I-I
chair	I-I
and	O
appear	B-I
relaxed	I-I
while	O
being	O
evaluated	O
.	O

Half	O
of	O
the	O
participants	O
heard	O
their	B-O
heart	I-O
sounds	I-O
first	O
via	O
headphones	O
and	O
then	O
via	O
loudspeakers	O
which	O
were	O
also	O
audible	O
to	O
observers	O
.	O

The	O
presentation	O
order	O
of	O
the	O
heart	O
sound	O
was	O
reversed	O
for	O
the	O
other	O
half	O
of	O
the	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	O
arterial	O
disease	O
:	O
therapeutic	O
confidence	O
of	O
CT	B-I
versus	O
digital	B-I
subtraction	I-I
angiography	I-I
and	O
effects	O
on	O
additional	O
imaging	O
recommendations	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
controlled	O
trial	O
,	O
73	O
patients	O
were	O
assigned	O
to	O
CT	B-I
angiography	I-I
,	O
and	O
72	O
were	O
assigned	O
to	O
DSA	B-I
.	O

Physician	B-O
confidence	I-O
in	O
the	O
treatment	O
decision	O
was	O
measured	O
as	O
a	O
continuous	O
outcome	O
on	O
a	B-O
scale	I-O
of	I-O
0	I-O
-	I-O
10	I-O
(	I-O
uncertain	I-O
to	I-O
certain	I-O
)	I-O
and	O
as	O
a	B-O
dichotomous	I-O
outcome	I-O
(	I-O
further	I-O
imaging	I-O
recommended	I-O
,	I-O
yes	I-O
or	I-O
no	I-O
)	I-O
.	O

Mean	B-O
confidence	I-O
scores	I-O
and	O
additional	B-O
imaging	I-O
recommendations	I-O
were	O
compared	O
between	O
CT	B-I
and	O
DSA	B-I
groups	O
in	O
an	O
intention	O
-	O
to	O
-	O
diagnose	O
-	O
and	O
-	O
treat	O
analysis	O
.	O

To	O
detect	O
trends	O
in	O
confidence	O
,	O
confidence	O
scores	O
were	O
plotted	O
over	O
time	O
,	O
and	O
multiple	O
linear	O
regression	O
analysis	O
was	O
performed	O
.	O

To	O
detect	O
trends	O
in	O
additional	O
imaging	O
recommendations	O
,	O
logistic	O
regression	O
analysis	O
was	O
used	O
.	O

Data	O
from	O
eligible	O
nonrandomized	O
patients	O
were	O
analyzed	O
separately	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
ibuprofen	B-I
on	O
cyclooxygenase	O
and	O
nitric	O
oxide	O
synthase	O
of	O
gastric	O
mucosa	O
:	O
correlation	O
with	O
endoscopic	O
lesions	O
and	O
adverse	O
reactions	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
Helicobacter	I-P
pylori	I-P
-	I-P
negative	I-P
subjects	I-P
were	O
randomized	O
to	O
treatment	O
with	O
ibuprofen	B-I
or	O
ibuprofen	B-I
-	I-I
arginate	I-I
(	O
each	O
600	O
mg	O
/	O
6	O
hr	O
during	O
3	O
days	O
)	O
.	O

Endoscopies	B-O
were	O
performed	O
1	O
week	O
before	O
and	O
after	O
treatment	O
.	O

Biopsies	B-O
were	O
taken	O
from	O
the	B-O
gastric	I-O
antrum	I-O
and	O
corpus	B-O
for	O
determination	B-O
of	I-O
prostaglandin	I-O
E2	I-O
(	I-O
PGE2	I-O
)	I-O
by	O
ELISA	B-O
and	O
cyclooxygenase	B-O
(	B-O
COX	I-O
-	I-O
1	I-O
and	O
COX	B-O
-	I-O
2	I-O
)	I-O
and	O
nitric	B-O
oxide	I-O
synthase	I-O
(	B-O
eNOS	I-O
and	O
iNOS	B-O
)	I-O
by	O
western	B-O
blot	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Risperidone	B-I
in	O
the	O
treatment	O
of	O
disruptive	O
behavioral	O
symptoms	O
in	O
children	B-P
with	I-P
autistic	I-P
and	I-P
other	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	O

METHODS	O
:	O
In	O
this	O
8	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
risperidone	B-I
/	O
placebo	B-C
solution	I-C
(	O
0	O
.	O
01	O
-	O
0	O
.	O

06	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
79	B-P
children	I-P
who	I-P
were	I-P
aged	I-P
5	I-P
to	I-P
12	I-P
years	I-P
and	I-P
had	I-P
PDD	I-P
.	O

Behavioral	B-O
symptoms	I-O
were	O
assessed	O
using	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
,	O
Nisonger	B-O
Child	I-O
Behavior	I-O
Rating	I-O
Form	I-O
,	O
and	O
Clinical	B-O
Global	I-O
Impression	I-O
-	I-O
Change	I-O
.	O

Safety	B-O
assessments	O
included	O
vital	B-O
signs	I-O
,	O
electrocardiogram	B-O
,	O
extrapyramidal	B-O
symptoms	I-O
,	O
adverse	B-O
events	I-O
,	O
and	O
laboratory	B-O
tests	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
antioxidants	B-I
,	O
zinc	B-I
,	O
and	O
copper	B-I
on	O
cognition	O
in	O
the	B-P
elderly	I-P
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Participants	B-P
in	I-P
the	I-P
Age	I-P
-	I-P
Related	I-P
Eye	I-P
Disease	I-P
Study	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
daily	B-I
antioxidants	I-I
(	O
vitamin	B-I
C	I-I
,	O
500	O
mg	O
;	O
vitamin	B-I
E	I-I
,	O
400	O
IU	O
;	O
beta	B-I
carotene	I-I
,	O
15	O
mg	O
)	O
,	O
zinc	B-I
and	O
copper	B-I
(	O
zinc	B-I
,	O
80	O
mg	O
;	O
cupric	B-I
oxide	I-I
,	O
2	O
mg	O
)	O
,	O
antioxidants	B-I
plus	O
zinc	B-I
and	O
copper	B-I
,	O
or	O
placebo	B-C
.	O

A	B-O
cognitive	I-O
battery	I-O
was	O
administered	O
to	O
2	B-P
,	I-P
166	I-P
elderly	I-P
persons	I-P
after	I-P
a	I-P
median	I-P
of	I-P
6	I-P
.	I-P
9	I-P
years	I-P
of	I-P
treatment	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Syncope	O
Evaluation	O
in	O
the	O
Emergency	O
Department	O
Study	O
(	O
SEEDS	O
)	O
:	O
a	O
multidisciplinary	O
approach	O
to	O
syncope	B-I
management	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Dual	O
-	O
task	O
-	O
related	O
gait	O
changes	O
in	O
transitionally	B-P
frail	I-P
older	I-P
adults	I-P
:	O
the	O
type	O
of	O
the	O
walking	O
-	O
associated	O
cognitive	O
task	O
matters	O
.	O

METHODS	O
:	O
Gait	O
was	O
tested	O
in	O
30	B-P
transitionally	I-P
frail	I-P
older	I-P
adults	I-P
(	I-P
mean	I-P
age	I-P
82	I-P
.	I-P
6	I-P
+	I-P
/	I-P
-	I-P
7	I-P
.	I-P
1	I-P
years	I-P
,	I-P
90	I-P
%	I-P
female	I-P
)	I-P
while	O
either	O
walking	B-I
alone	I-I
,	O
performing	B-I
a	I-I
simple	I-I
arithmetic	I-I
task	I-I
,	O
or	O
performing	B-I
a	I-I
task	I-I
of	I-I
verbal	I-I
fluency	I-I
.	O

Walking	B-O
time	I-O
in	I-O
seconds	I-O
,	O
number	B-O
of	I-O
steps	I-O
,	O
frequency	B-O
of	I-O
lateral	I-O
line	I-O
stepping	I-O
-	I-O
over	I-O
,	O
and	O
stops	B-O
were	O
recorded	O
.	O

Health	B-O
status	I-O
was	O
assessed	O
using	O
standard	B-O
instruments	I-O
of	I-O
geriatric	I-O
assessment	I-O
.	O

The	O
classification	O
of	O
Speechley	B-O
and	I-O
Tinetti	I-O
was	O
used	O
to	O
define	O
the	B-O
participants	I-O
'	I-O
degree	I-O
of	I-O
frailty	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
and	O
reflectance	B-I
-	I-I
mode	I-I
confocal	I-I
microscopy	I-I
as	O
adjunct	O
modalities	O
to	O
Mohs	O
micrographic	O
surgery	O
for	O
treatment	O
of	O
basal	O
cell	O
carcinoma	O
.	O

METHODS	O
:	O
Subjects	O
applied	O
study	B-I
cream	I-I
to	I-I
one	I-I
biopsy	I-I
-	I-I
confirmed	I-I
basal	I-I
cell	I-I
carcinoma	I-I
tumor	I-I
5	O
x	O
/	O
week	O
for	O
2	O
,	O
4	O
,	O
or	O
6	O
weeks	O
in	O
this	O
vehicle	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Confocal	B-I
microscopy	I-I
was	O
used	O
for	O
the	O
6	O
-	O
week	O
treatment	O
group	O
to	O
examine	O
the	B-O
target	I-O
tumor	I-O
area	I-O
at	O
each	O
interval	O
visit	O
and	O
immediately	O
before	O
Mohs	O
micrographic	O
surgery	O
.	O

After	O
the	O
Mohs	O
micrographic	O
surgery	O
excision	O
,	O
the	B-O
tissue	I-O
was	O
evaluated	O
histologically	B-O
,	O
and	O
the	B-O
excision	I-O
area	I-O
was	O
measured	O
.	O

Confocal	B-O
microscopy	I-O
readings	I-O
were	O
correlated	O
to	O
the	B-O
histologic	I-O
diagnosis	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
-	I-I
based	I-I
HIV	I-I
risk	I-I
reduction	I-I
intervention	I-I
for	O
adolescent	B-P
girls	I-P
:	O
evidence	O
of	O
feasibility	O
and	O
efficacy	O
.	O

METHODS	O
:	O
The	B-O
feasibility	I-O
of	O
the	O
intervention	O
was	O
demonstrated	O
by	O
successfully	O
implementing	O
it	O
with	O
33	O
sexually	O
-	O
active	O
,	O
single	O
girls	O
.	O

Preliminary	O
evidence	O
of	O
the	B-O
efficacy	I-O
of	O
the	O
intervention	O
was	O
obtained	O
using	O
a	O
randomized	O
trial	O
with	O
62	B-P
sexually	I-P
-	I-P
active	I-P
,	I-P
single	I-P
girls	I-P
.	O

